Skip to main navigation

Skip to Content

Overview
Stock Information
- Stock Quote & Chart
- Analyst Coverage
News & Events
Financial Information
- SEC Filings
Corporate Governance
IR Resources
- Contact IR
- Email Alerts

News Releases

Year

May 10, 2022

Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights

May 04, 2022

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

May 02, 2022

Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical Development at ASGCT Annual Meeting

Mar 29, 2022

Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

Mar 08, 2022

Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Jan 31, 2022

Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer

Jan 24, 2022

Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK

Jan 04, 2022

Lyell Immunopharma to Participate in 40th Annual J.P. Morgan Healthcare Conference

Print

Email Alerts

RSS Feeds

Contact IR

Home

Our Story

Our Team

Our Platforms

Our Pipeline

Join Us

| Privacy Policy

Copyright © 2022 Lyell Immunopharma, Inc.. All rights reserved.